What is the efficacy of intradetrusor onabotulinumtoxinA (OBA) for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS)?

Updated: Dec 04, 2020
  • Author: Eric S Rovner, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

Other long-term studies have shown improvements in pain scores, with symptom relief lasting from 6-12 months, with an average duration of relief of 9.9 months. [103] Evidence indicates that location of injection of OBA is important. In a small 2011 study, investigators attempted to block urethral visceral afferent fibers with OBA. No improvement in pain symptoms was noted. [104] This is in contrast to other studies, in which OBA was injected directly into the detrusor muscle or trigone. [103] Unfortunately, the heterogeneity of studies with OBA has prevented effective meta-analysis, despite these studies suggesting a trend toward short-term benefit. [105]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!